Peptidyl allyl sulfones
The present disclosure provides compositions for inhibiting proteases, methods for synthesizing the compositions, and methods of using the disclosed protease inhibitors. Aspects of the disclosure include peptidyl allyl sulfone compositions that inhibit proteases, for example cysteine proteases, either in vivo or in vitro.
1. A compound of the formula:
wherein,
R 1 is selected from the group consisting of phenyl-O—CO— and phenyl-O—CO—AA 1 ;
AA 1 , is an aliphatic amino acid with the L configuration, D configuration, or no chirality at the alpha-carbon, wherein AA 1 is selected from the group consisting of alanine, valine, leucine, isoleucine, norleucine, and norvaline,
R 2 is C 1-10 alkyl substituted with phenyl;
R 3 is selected independently from the group consisting of phenyl, phenyl monosubstituted with K, phenyl disubstituted with K, phenyl trisubstituted with K, C 1-10 alkyl with a phenyl group attached to the C 1-10 alkyl, C 1-10 alkyl with an attached phenyl group monosubstituted with K, C 1-10 alkyl with an attached phenyl group disubstituted with K, C 1-10 alkyl with an attached phenyl group trisubstituted with K,
K is selected from the group consisting of halogen, C 1-10 alkyl, C 1-10 perfluoroalkyl, C 1-10 alkoxy, phenoxy, NO 2, CN, OH, CO 2 H, CONH 2, amino, C 1-10 alkylamino, C 2-12 dialkylamino, C 1-10 acyl, and C 1-10 alkoxy-CO—, and C 1-10 alkyl-S—;
or a pharmaceutically acceptable salt, hydrate or solvate thereof.
2. The compound of claim 1 , wherein the double bond carbons have stereochemistry selected from the group consisting of cis, trans, E, and Z.
3. The compound of claim 1 , wherein:
AA 1 is selected from the group consisting of alanine, valine, and leucine;
R 2 is C 1 alkyl substituted with phenyl; and
R 3 is phenyl.
4. The compound of claim 1 , wherein:
R 1 is phenyl-O—CO—;
R 2 is C 1 alkyl substituted with phenyl; and
R 3 is phenyl.
5. The compound of claim 1 , wherein the compound is selected from the group consisting of Cbz-Ala-Phe-AS-Ph, Cbz-Val-Phe-AS-Ph, and Cbz-Leu-Phe-AS-Ph, wherein AS is an allyl sulfone.
6. The compound of claim 1 , wherein the compound is Cbz-Phe-AS-Ph, wherein AS is an allyl sulfone.
7. The compound of claim 1 , wherein said compound specifically inhibits cysteine proteases.
8. A pharmaceutical composition comprising an effective amount of a compound of claim 1 .
9. The pharmaceutical composition of claim 8 , further comprising a pharmaceutically acceptable carrier.